After the success of its anti-obesity medicine, Novo Nordisk fell on the Copenhagen inventory change by nearly 10% as a result of scientific failure of certainly one of its medicine for Alzheimer’s. The group introduced that an oral model of its semaglutide drug failed to fulfill its fundamental objective in late-stage scientific trials aimed toward testing whether or not the drug can sluggish cognitive decline in Alzheimer’s sufferers.
The Alzheimer’s market
The information is important for Novo, as Alzheimer’s illness would characterize a big new marketplace for GLP-1 medicine reminiscent of semaglutide, following profitable success in treating weight problems and diabetes. Alzheimer’s sufferers at present have restricted therapy choices. The drug being examined is Novo’s Rybelsus, a tablet at present authorized just for the therapy of kind 2 diabetes. Both Rybelsus and Novo’s blockbuster medicine, Ozempic and Wegovy, are primarily based on the identical lively ingredient, semaglutide, a GLP-1 drug
https://www.ilsole24ore.com/art/novo-nordisk-tracolla-farmaco-l-alzheimer-AHQ7mivD